Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Common Equity (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Common Equity for 4 consecutive years, with $301.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Common Equity fell 39.58% to $301.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $301.6 million, a 39.58% decrease, with the full-year FY2024 number at $401.5 million, up 69.97% from a year prior.
  • Common Equity was $301.6 million for Q3 2025 at Centessa Pharmaceuticals, down from $344.9 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $499.1 million in Q3 2024 to a low of $215.2 million in Q1 2024.
  • A 4-year average of $340.7 million and a median of $336.2 million in 2022 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: surged 92.43% in 2024, then tumbled 39.58% in 2025.
  • Centessa Pharmaceuticals' Common Equity stood at $336.2 million in 2022, then decreased by 29.72% to $236.2 million in 2023, then surged by 69.97% to $401.5 million in 2024, then fell by 24.9% to $301.6 million in 2025.
  • Per Business Quant, the three most recent readings for CNTA's Common Equity are $301.6 million (Q3 2025), $344.9 million (Q2 2025), and $386.2 million (Q1 2025).